15
3.4.4: In individuals aged >75 years without diabetes and a 10-
year risk ≥7.5%, ES recommends discussing the benefits of statin
therapy with the patient based on expected benefits versus possible
risks/side effects. (1|⊕⊕⊕
)
Technical Remarks:
▶ Decisions should be made on a case-by-case basis depending on estimates of likely
benefits vs. risks in individual patients.
▶ Statin therapy should be calibrated to reach the recommended LDL targets.
➤ 3.5: In individuals at metabolic risk who are taking statins with adequate
LDL-C reduction, elevated triglyceride levels [≥200 mg/dL (2.3 mmol/L)],
and reduced HDL levels [≤50 mg/dL (1.3 mmol/L) in females, or ≤40 mg/dL
(1.0 mmol/L) in males], ES suggests considering fenofibrate adjunct
therapy. (2|⊕⊕⊕
)
Technical Remarks:
▶ Avoid gemfibrozil in this situation.
➤ 3.6: In individuals aged 40 years and older at metabolic risk with LDL-C
at target, an estimated 10-year ASCVD risk of >7.5% and without clinical
ASCVD or other ASCVD risk factors, ES suggests treatment with a
moderate-intensity statin. (2|⊕⊕⊕
)
